Skip to main content
OpenTrials
Completed

NCT Number: NCT00442065

ARBITER-II: Aorfix™ Bifurcated Safety and Performance Trial: Phase II, Angulated Vessels

To assess the safety and performance of Aorfix™ Stent Grafts in the treatment of Abdominal Aortic and Aorto-Iliac Aneurysm where a significant degree of vessel angulation exists at the neck of the aneurysm or in the common iliac arteries.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

2 Interni Klinika; General University Hospital, Prague, Czechia

Loading trial locations.

About this study

The Aorfix™ Stent Graft is currently a CE-marked product indicated for AAA where the angle of the aneurysm is <65o. The objective of this study is to evaluate the safety and performance of the bifurcated Aorfix™ Stent Graft in the treatment of infrarenal abdominal aortic aneurysms and aorto-iliac aneurysms, in infrarenal necks angulated > 60o (between 60 to 90 degrees) as measured by 3-dimensional reconstruction in order to widen the indication.

The investigation is a prospective open label, single arm, multi-centre clinical study. The study group will consist of 25 evaluable participants. In order to account for patients lost to follow up (estimated at approximately 20%) up to 30 patients will be enrolled in the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of abdominal aortic aneurysm 50 mm or larger in diameter, 40 mm or larger in diameter if symptomatic (i.e. pain, embolisation), or documented AAA growth of more than 5 mm within the previous 6 months, and/or including extension into common iliac artery(ies), or any saccular aneurysm.
  • Infrarenal neck with a minimum length of 15 mm and a neck angulation between 60° and 90°, as assessed in 3 dimensions.
  • The iliac artery diameter must be of appropriate diameter (1 mm smaller than the device diameter), with an appropriate distal landing length. The tortuosity of the common or external iliac arteries or femoral arteries must be low to medium (refer to operations manual).
  • Patient provides written informed consent.
  • Patients >18 years who are suitable for endovascular repair.
  • Patient fit for endovascular surgery, with a diameter at the access sites of 7mm or larger bilaterally.
  • Patient has a life expectancy longer than the duration of the study.

Exclusion criteria

  • Patient has a ruptured aneurysm.
  • Patient has insufficient length of proximal aneurysm neck (<15mm from aneurysm to lowest renal artery and <20 mm from the aneurysm to the SMA).
  • Aneurysm extends above renal arteries.
  • Proximal neck of aneurysm has significant loose thrombus associated with it, or significant circumferential calcifications.
  • Pregnant or nursing patients.
  • Patient unfit for bail-out surgery and appropriate anaesthesia.
  • Patient with an acute or chronic aortic dissection or mycotic aneurysm (defined by localised asymmetric aneurysm sac).
  • Patient has current non-localised infection.
  • Patient has known allergy to graft materials, Nitinol, or contrast media.
  • Patient's where imaging is problematic; an example is an obese patient.
  • Patient has co-morbidities that deny vascular access, including small / tortuous access vessels.

Treatment and study plan

Aorfix™ Stent Grafts (AAA endovascular procedure)

Device

Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System

Other names: Aorfix™

Primary outcomes

  1. The primary endpoints are acute technical success, initial performance and safety at 1-month follow up.

    Time frame: 1-month post-procedure

Secondary outcomes

  1. Secondary endpoints will examine recovery factors: operative time, ICU duration, blood loss, days to normal diet, days to discharge, days to ambulation, freedom from non-clinical events, need for secondary procedure and conversion to uni-iliac.

    Time frame: 6-months post-procedure

  2. As well as safety at 6-month follow-up as measured by serious adverse events that occur up to 6-months post-procedure.

    Time frame: 6-months post-procedure

Sponsors and collaborators

Lead sponsor

Lombard Medical

Industry

Registry information

Official study title

A Study to Assess the Acute Technical Success of Aorfix™ Stent Grafts in the Treatment of Abdominal Aortic and Aorto-Iliac Aneurysm Where a Significant Degree of Vessel Angulation Exists at the Neck of the Aneurysm

Acronym: ARBITER-II

Important dates

Study start
2006
Primary completion
2009
Study completion
2009
First posted
Mar 1, 2007
Registry last updated
Oct 17, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.